The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention
Abstract
A workshop was convened by the International Diabetes Federation to review the latest information relating to the risks associated with impaired glucose tolerance (IGT) and impaired fasting glycaemia (IFG) for future diabetes and cardiovascular disease (CVD). The workshop sought to address three questions: (i) are the current definitions of IGT and IFG appropriate; (ii) are IFG and IGT risk factors, risk markers or diseases; (iii) what interventions (if any) should be recommended for people with IFG and IGT? The determinants of elevated fasting glucose and 2-h plasma glucose in an oral glucose tolerance test (2-HPG) levels differ. Raised hepatic glucose output and a defect in early insulin secretion are characteristic of the former, and peripheral insulin resistance is most characteristic of the latter. Therefore, it is not surprising that the concordance between the categories of IFG and IGT is limited. In all prevalence studies to date only half or less of people with IFG have IGT, and even a lower proportion (20-30%) with IGT also have IFG. In the majority of populations studied, IGT is more prevalent than IFG, and there is a difference in phenotype and gender distribution between the two categories. IFG is substantially more common amongst men and IGT slightly more common amongst women. The prevalence of IFG tends to plateau in middle age whereas the prevalence of IGT rises into old age. Both IFG and IGT are associated with a substantially increased risk of developing diabetes, with the highest risk in people with combined IFG and IGT. Because IGT is commoner than IFG in most populations it is more sensitive (but slightly less specific) for identifying people who will develop diabetes. In most populations studied, 60% of people who develop diabetes have either IGT or IFG 5 years or so before, with the other 40% having normal glucose tolerance at that time. The limited published data suggest that both isolated IFG (I-IFG) and isolated IGT (I-IGT) are similarly associated with cardiovascular risk factors, such as hypertension and dyslipidaemia, with the highest risk in those with combined IFG and IGT. However, some data have suggested that I-IGT is more strongly associated with hypertension and dyslipidaemia (features of the metabolic syndrome) than I-IFG. In unadjusted analyses both IFG and IGT are associated with CVD and total mortality. In separate analyses for fasting and 2-HPG adjusted for other cardiovascular risk factors (from the DECODE study) there remains a continuous relationship between 2-HPG and mortality, but an independent relationship with fasting glucose is only found above 7.0 mmol/l. Glycated haemoglobin (HbA1c) levels are continuously and positively associated with CVD and total mortality independent of other CVD risk factors. Life style interventions, including weight loss and increased physical activity, are highly effective in preventing or delaying the onset of diabetes in people with IGT. Two randomized controlled trials of individuals with IGT found that life style intervention studies reduce the risk of progressing to diabetes by 58%. The oral hypoglycaemic drugs metformin and acarbose have also been shown to be effective, but less so than the life style measures. Similar data do not yet exist for the effectiveness of such interventions in people with I-IFG. Larger studies are required to evaluate the effects of interventions on cardiovascular outcomes in people with IGT. Cost effective strategies to identify people with IGT for intervention should be developed and evaluated. The use of simple risk scores to assess who should undergo an oral glucose tolerance test is one promising approach, although these will need to be population-specific. In conclusion, IGT and IFG differ in their prevalence, population distribution, phenotype, and risk of total mortality and CVD. The consensus of the workshop was: 1. The diagnostic thresholds for all categories of glucose intolerance should be revisited in the light of the latest evidence. There was no clear consensus (with current evidence) on whether IFG and IGT should be classified as diseases, but they clearly represent risk factors and risk markers for diabetes and CVD, respectively. 2. Both IGT and IFG are similarly associated with an increased risk of diabetes, but IGT is more strongly associated with CVD outcomes. 3. Risks are higher when IGT and IFG coexist. 4. Life style interventions are highly effective in delaying or preventing the onset of diabetes in people with IGT and may reduce CVD and total mortality, but the latter requires formal testing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
Pan, X.-R., Li, G.-W., Hu, Y.-H., Wang, J.-X., Yang, W.-Y., An, Z.-X., Hu, Z.-X., Juan-Lin, Xiao, J.-Z., Cao, H.-B., et al. (1997) · Diabetes Care · doi:10.2337/diacare.20.4.537 · Cited by 4,320
Sick individuals and sick populations
Rose, G. (2001) · International Journal of Epidemiology · doi:10.1093/ije/30.3.427 · Cited by 3,736
Sick individuals and sick populations
ROSE, G. (1985) · International Journal of Epidemiology · doi:10.1093/ije/14.1.32 · Cited by 2,701
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., & Laakso, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08905-5 · Cited by 2,543
Lindström, J., & Tuomilehto, J. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.725 · Cited by 1,862
Coutinho, M., Gerstein, H. C., Wang, Y., & Yusuf, S. (1999) · Diabetes Care · doi:10.2337/diacare.22.2.233 · Cited by 1,685
Glucose Tolerance and Cardiovascular Mortality: Comparison of Fasting and 2-Hour Diagnostic Criteria
(2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.3.397 · Cited by 1,371
(1999) · The Lancet · doi:10.1016/s0140-6736(98)12131-1 · Cited by 1,313
Borch‐Johnsen, K., Neil, A., Balkau, B., Larsen, S. H., Nissinen, A. E. T., Pekkanen, J., Keinanen-Kiukaanniemi, S. M., Hiltunen, L. A., Kivelä, S., Tuomilehto, J. O., et al. (1999) · The Lancet · Cited by 1,272
Self-citationPharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173
Khaw, K.-T. (2001) · BMJ · doi:10.1136/bmj.322.7277.15 · Cited by 1,017
The Rising Prevalence of Diabetes and Impaired Glucose Tolerance
Dunstan, D. W., Zimmet, P. Z., Welborn, T. A., de Courten, M. P., Cameron, A. J., Sicree, R. A., Dwyer, T., Colagiuri, S., Jolley, D., Knuiman, M., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.5.829 · Cited by 907
Self-citationFreeman, D. J., Norrie, J., Sattar, N., Neely, R. D. G., Cobbe, S. M., Ford, I., Isles, C., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., et al. (2001) · Circulation · doi:10.1161/01.cir.103.3.357 · Cited by 844
Diabetes and Cardiovascular Disease: The “Common Soil” Hypothesis
Stern, M. P. (1995) · Diabetes · doi:10.2337/diab.44.4.369 · Cited by 739
de Vegt, F., Dekker, J. M., Ruhé, H. G., Stehouwer, C. D. A., Nijpels, G., Bouter, L. M., & Heine, R. J. (1999) · Diabetologia · doi:10.1007/s001250051249 · Cited by 613
Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts
The DECODE Study Group (2003) · Diabetes Care · doi:10.2337/diacare.26.1.61 · Cited by 608
Gabir, M. M., Hanson, R. L., Dabelea, D., Imperatore, G., Roumain, J., Bennett, P. H., & Knowler, W. C. (2000) · Diabetes Care · doi:10.2337/diacare.23.8.1108 · Cited by 568
[WHO Expert Committee on diabetes mellitus].
Reitsma, W. D., & Terpstra, J. (1981) · PubMed · Cited by 556
Nonhypoglycemic Effects of Thiazolidinediones
Parulkar, A. A., Pendergrass, M. L., Granda-Ayala, R., Lee, T. R., & Fonseca, V. A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-1-200101020-00014 · Cited by 412
Age- and Sex-Specific Prevalence of Diabetes and Impaired Glucose Regulation in 11 Asian Cohorts
the DECODA Study Group (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1770 · Cited by 396
Shaw, J. E., Zimmet, P. Z., de Courten, M., Dowse, G. K., Chitson, P., Gareeboo, H., Hemraj, F., Fareed, D., Tuomilehto, J., & Alberti, K. G. (1999) · Diabetes Care · doi:10.2337/diacare.22.3.399 · Cited by 329
Self-citationLithell, H., & Zethelius, B. (1998) · Cited by 304
Weyer, C., Bogardus, C., & Pratley, R. E. (1999) · Diabetes · doi:10.2337/diabetes.48.11.2197 · Cited by 292
Fontbonne, A., Charles, M. A., Juhan-Vague, I., Bard, J. M., André, P., Isnard, F., Cohen, J. M., Grandmottet, P., Vague, P., Safar, M. E., et al. (1996) · Diabetes Care · doi:10.2337/diacare.19.9.920 · Cited by 281
Harris, M. I., Eastman, R. C., Cowie, C. C., Flegal, K. M., & Eberhardt, M. S. (1997) · Diabetes Care · doi:10.2337/diacare.20.12.1859 · Cited by 264
Leger, A. S. S. (1996) · Journal of Epidemiology and Community Health · doi:10.1136/jech.50.2.229-b · Cited by 218
Gabir, M. M., Hanson, R. L., Dabelea, D., Imperatore, G., Roumain, J., Bennett, P. H., & Knowler, W. C. (2000) · Diabetes Care · doi:10.2337/diacare.23.8.1113 · Cited by 211
Comparison of the fasting and the 2-h glucose criteria for diabetes in different Asian cohorts
Qiao, Q., Nakagami, T., Tuomilehto, J., Borch-Johnsen, K., Balkau, B., Iwamoto, Y., & Tajima, N. (2000) · Diabetologia · doi:10.1007/s001250051557 · Cited by 207
Performance of a predictive model to identify undiagnosed diabetes in a health care setting.
Baan, C. A., Ruige, J. B., Stolk, R. P., Witteman, J. C., Dekker, J. M., Heine, R. J., & Feskens, E. J. (1999) · Diabetes Care · doi:10.2337/diacare.22.2.213 · Cited by 183
Chiasson, J.-L., Gomis, R., Hanefeld, M., Josse, R. G., Karasik, A., Laakso, M., & The Stop-Niddm Trial Research Group (1998) · Diabetes Care · doi:10.2337/diacare.21.10.1720 · Cited by 182
Thiazolidinediones and liver toxicity.
Scheen, A. J. (2001) · PubMed · Cited by 178
Fasting proinsulin concentrations predict the development of type 2 diabetes.
Wareham, N. J., Byrne, C. D., Williams, R., Day, N. E., & Hales, C. N. (1999) · Diabetes Care · doi:10.2337/diacare.22.2.262 · Cited by 173
Impaired fasting glucose or impaired glucose tolerance
Shaw, J. E., Zimmet, P., de Courten, M., Gk, D., Chitson, P., Gareeboo, H., Hemraj, F., Fareed, D., Tuomilehto, J., & Kgmm., A. (1999) · STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) · Cited by 169
Self-citationAzen, S. P., Peters, R. K., Berkowitz, K. M., Kjos, S. L., Xiang, A. H., & Buchanan, T. A. (1998) · Controlled Clinical Trials · doi:10.1016/s0197-2456(97)00151-7 · Cited by 153
de Vegt, F., Dekker, J. M., Stehouwer, C. D. A., Nijpels, G., Bouter, L. M., & Heine, R. J. (1998) · Diabetes Care · doi:10.2337/diacare.21.10.1686 · Cited by 153
Impaired glucose tolerance and fasting hyperglycaemia have different characteristics
Davies, M. J., Raymond, N. T., Day, J., Hales, C. N., & Burden, A. C. (2000) · Diabetic Medicine · doi:10.1046/j.1464-5491.2000.00246.x · Cited by 143
Performance of an NIDDM Screening Questionnaire Based on Symptoms and Risk Factors
Ruige, J. B., de Neeling, J. N. D., Kostense, P. J., Bouter, L. M., & Heine, R. J. (1997) · Diabetes Care · doi:10.2337/diacare.20.4.491 · Cited by 139
Hanefeld, M., Koehler, C., Henkel, E., Fuecker, K., Schäper, F., & Temelkova-Kurktschiev, T. S. (2000) · Diabetic Medicine · doi:10.1046/j.1464-5491.2000.00408.x · Cited by 118
Risk of diabetes in the new diagnostic category of impaired fasting glucose: a prospective analysis.
Vaccaro, O., Ruffa, G., Imperatore, G., Iovino, V., Rivellese, A. A., & Riccardi, G. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1490 · Cited by 118
Larsson, H. E., & Åhrén, B. (1998) · Diabetologia · doi:10.1007/s001250050986 · Cited by 105
Impaired fasting glucose is not a risk factor for atherosclerosis
Hanefeld, M., Temelkova-Kurktschiev, T. S., Schäper, F., Henkel, E., Siegert, G., & Koehler, C. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00072.x · Cited by 88
Reproducibility of the Diagnosis of Diabetes Over a 30-Month Follow-Up
Eschwège, É., Charles, M.-A. A., Simon, D., Thibult, N., & Balkau, B. (2001) · Diabetes Care · doi:10.2337/diacare.24.11.1941 · Cited by 68
Comparison of ADA and WHO criteria for diagnosis of diabetes and glucose intolerance
Available, N. A. N. (1998) · Diabetologia · doi:10.1007/s001250051040 · Cited by 64
Interactions of Impaired Glucose Transport and Phosphorylation in Skeletal Muscle Insulin Resistance
Williams, K. V., Price, J. C., & Kelley, D. E. (2001) · Diabetes · doi:10.2337/diabetes.50.9.2069 · Cited by 61
Gimeno, S. G. A., Ferreira, S. R. G., Franco, L. J., & Iunes, M. (1998) · Diabetes Care · doi:10.2337/diacare.21.11.1889 · Cited by 60
Ko, G. T. C., Chan, J. C. N., Woo, J., & Cockram, C. S. (1998) · Diabetes Care · doi:10.2337/diacare.21.12.2094 · Cited by 60
Uchino, H., Niwa, M., Shimizu, T., Nishiyama, K., & Kawamori, R. (2000) · Endocrine Journal · doi:10.1507/endocrj.47.639 · Cited by 49
Transient impaired glucose tolerance in Pima Indians: is it important?
Saad, M. F., Knowler, W. C., Pettitt, D. J., Nelson, R. G., & Bennett, P. H. (1988) · BMJ · doi:10.1136/bmj.297.6661.1438 · Cited by 48
Buchanan, T. A., Xiang, A. S., Peters, R., Kjos, S. L., Marroquin, A., Goico, J., Ochoa, C., Tan, S., & Azen, S. (2001) · Cited by 27
Motala, A. A., Omar, M. A. K., & Gouws, E. (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1101 · Cited by 21
Available, N. A. N. (1999) · Diabetologia · doi:10.1007/s001250051305 · Cited by 18
Diabetes: From Research to Clinical Practice.
Islam, M. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_553 · Cited by 15
Thompson, W. G. (2001) · Mayo Clinic Proceedings · doi:10.4065/76.11.1137 · Cited by 12
Cited by
Follow-up report on the diagnosis of diabetes mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3160 · Cited by 3,784
Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus
Kautzky-Willer, A., Harreiter, J., & Pacini, G. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1137 · Cited by 2,043
Obesity, Metabolic Syndrome, and Cardiovascular Disease
Grundy, S. M. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0372 · Cited by 1,371
Grundy, S. M. (2011) · Atlas of Atherosclerosis and Metabolic Syndrome · doi:10.1007/978-1-4419-5839-6_1 · Cited by 1,223
Metadata
- Authors
- Writing committee, Unwin, N., Shaw, J., Zimmet, P., & Alberti, K. G. M. M.
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2002-09
- Volume
- 19
- Issue
- 9
- Pages
- 708-723
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W1992777999
- Cited by
- 1,108
- References
- 61
- FWCI
- 22.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.